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In chronic thromboembolic pulmonary hypertension (CTEPH), stenoses or obstructions of
the pulmonary arteries due to organized thrombi can cause an elevation in pulmonary artery
resistance, which in turn can result in pulmonary hypertension. CTEPH can be cured surgi-
cally by pulmonary endarterectomy (PEA); however, patients deemed unsuitable for PEA
due to lesion, advanced age, or comorbidities have a poor prognosis and limited treatment
options. Recently, advances have been made in balloon pulmonary angioplasty for these
patients, and this review highlights this recent progress.
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INTRODUCTION
Chronic thromboembolic pulmonary hypertension (CTEPH) is
a form of pulmonary hypertension classified as Group 4 (1). In
CTEPH, stenoses or obstructions of the pulmonary arteries due
to organized thrombi can cause an elevation in the pulmonary
artery resistance, which may in turn result in pulmonary hyperten-
sion (Figure 1). Previously, the prognosis of patients with CTEPH
whose mean pulmonary arterial pressure (PAP) is>30 mmHg was
very poor, if left untreated, at only 10% at 3 years (2).
The only established and potentially curative treatment cur-
rently available for CTEPH is pulmonary endarterectomy (PEA)
(3); however, PEA can only be performed at a limited number of
institutions at the present time, as the surgical technique requires
proficiency and intermittent total circulatory arrest under deep
hypothermia (4, 5). Although the postoperative outcome was
reportedly worse in patients with distal thrombi, at expert cen-
ters, the outcomes of both proximal and distal cases are recently
reported to be excellent (5, 6). However, because patients of an
advanced age, with comorbidities, and with a poor general condi-
tion are ineligible for PEA, not all patients can undergo the surgery.
Based on the data from an international registry, 63% of the
patients with CTEPH were considered operable, 36% inoperable,
and 57% actually underwent surgery (7).
Although patients who are unsuitable for PEA are treated with
pulmonary hypertension-specific drugs, the efficacy of these drugs
for lowering the mean PAP in patients with CTEPH had not been
established (8). Riociguat,a stimulator of soluble guanylate cyclase,
has recently been reported to be effective for inoperable CTEPH or
persistent/recurrent pulmonary hypertension after PEA (9). The
riociguat group was observed to have a significant improvement
in the primary endpoint of 6-min walk distance. Pulmonary vas-
cular resistance significantly decreased and the NT-proBNP level
and WHO functional class were significantly improved. It is now
approved by the U.S. Food and Drug Administration, the European
Medicines Agency, and in Japan. However, its long-term efficacy is
not yet established. Moreover, medical therapy in CTEPH should
not be considered as a replacement for PEA (3) and riociguat is
approved only for selected patients as described above.
There is another treatment option for inoperable patients
with CTEPH, balloon pulmonary angioplasty (BPA). The latest
guideline for CTEPH states that there are numerous concerns
and unanswered questions about this technique and its role in
CTEPH remains uncertain and requires further evaluation before
it can be recommended as an established treatment for CTEPH
(3). Recently, advances have been made in BPA and this review
highlights its recent progress.
HISTORY OF REFINED BALLOON PULMONARY ANGIOPLASTY
Balloon pulmonary angioplasty is an interventional treatment that
uses a balloon catheter to dilate pulmonary stenoses (Figure 2).
BPA was first developed in the field of pediatric cardiology for
treating congenital hypoplastic and stenotic pulmonary arteries
(10), and since 1988, BPA has been performed for CTEPH cases
that are ineligible for PEA (11). A study published in 2001 summa-
rizing the outcomes for 18 CTEPH cases suggested that BPA was
effective (12). However, the procedure required improvement, as
the treatment effects were less than those obtained by PEA. Fur-
ther, BPA was found to be frequently associated with pulmonary
edema, which can be fatal. Later, two more cases with inopera-
ble CTEPH were reported to be improved by BPA (13). However,
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more than 20 years after the first report of BPA for CTEPH, BPA
is still not widely accepted as a therapeutic option for inoperable
patients.
Since 2004, we have been attempting to improve the BPA
procedure at our hospital. Because we had seen many patients
with CTEPH who were diagnosed as inoperable and suffered
from increasing disability in spite of treatment with pulmonary
hypertension-specific drugs. In Japan, there had been no spe-
cific drug available for treating CTEPH until September 2014
when riociguat was approved. Considering the high mortality of
these patients when untreated, we needed an alternative therapeu-
tic option. We had performed BPA on 68 patients by 2011 and
reported efficacy of BPA (14). With only one perioperative death,
FIGURE 1 | Organized thrombi in chronic thromboembolic pulmonary
hypertension. The histopathological findings indicated luminal narrowing
due to thrombi organized by fibrous intimal hyperplasia, containing
characteristic recanalized channels (known as colander lesions) of the
pulmonary artery (elastic tissue stain).
the safety of BPA was also improved compared with that previ-
ously reported (12). With the publishing of BPA studies from other
Japanese institutions (15, 16), BPA was covered at the Fifth World
Symposium on Pulmonary Hypertension (3). Now, attempts are
being made outside of Japan as well, and the efficacy of BPA has
been confirmed in selected patients (17–19).
INDICATIONS OF BPA
PATIENT FACTORS INFLUENCING THE INDICATION FOR BPA
Since PEA is the gold standard therapy for CTEPH, patients who
are not eligible for PEA are considered as candidates for BPA. Fur-
thermore, patients with residual or recurrent pulmonary hyper-
tension after PEA are also candidates in case repeated surgery is
judged to be difficult. Most importantly, the patients should be
informed about and understand the risks and benefits of both
PEA and BPA before undergoing either treatment.
Contraindications of BPA include iodine allergy, as the use
of a contrast medium is essential in BPA. Additionally, in cases
with renal dysfunction, the benefits of performing BPA must be
weighed against the risks. Severity of pulmonary hypertension may
not necessarily be a contraindication of BPA. Although previous
reports have indicated a higher mean PAP at baseline is associ-
ated with more frequent complications, the patient prognosis will
be worse without effective treatment in cases with severe hemo-
dynamics. BPA can be expected to have more powerful effect in
these patients. Indeed, recent studies, including mainly severely ill
patients with high mean PAP and low cardiac index, reported suc-
cessful treatment outcomes with BPA (14–16, 20, 21). Age is also
often considered, and the safety and efficacy of BPA in elderly
patients have already been reported in recent studies (14–16),
with the hemodynamic improvements being comparable between
younger and elderly patients (22). The prevalence of complications
was also comparable between these two groups.
According to the Japanese Circulation Society’s statement
regarding BPA, the candidates for BPA are described as follows: (1)
unsuitable cases for PEA (surgically inaccessible lesions, surgically
accessible but inoperable because of comorbidities, and cases of
residual or recurrent pulmonary hypertension after PEA); (2) cases
FIGURE 2 | Pulmonary angiography before and after balloon
pulmonary angioplasty (BPA). (A) Subtotal obstruction was noted in
the pulmonary angiography before BPA (arrow). (B) Pulmonary
angiography after BPA showed blood flow to the peripheral arteries
after balloon dilatation. The arrow indicates the same site as the arrow
in (A).
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in which conventional therapy is insufficient (WHO functional
class ≥III after conventional therapy, mean PAP ≥30 mmHg, or
PVR ≥300 dyne · s · cm−5); (3) patients who provide informed
consent (patients who want to be treated with BPA after fully
understanding the risks and benefits of both BPA and PEA); and
(4) cases without serious complications, multiorgan failure, or
iodine allergy (23).
INDICATION FOR EACH LESION
The most distinct difference between PEA and BPA is the dif-
ferent perception of the indication for lesions. In PEA, the orga-
nized thrombi are considered as a whole, and the indication for
surgery is made depending on the extent and location of the
organized thrombi. In contrast, in BPA, each individual artery
is evaluated for indication of BPA based on the lesion type and
distribution/location of the lesion.
In patients with CTEPH, lesions are generally present in most
arteries, and there is usually a mixture of various lesion types.
The classification of CTEPH is currently based on the endarterec-
tomized tissue removed by PEA (24). This is useful as it is easy to
understand the distribution of the organized thrombi. However, in
performing BPA, the angiographical classification is more useful
in evaluating the lesion types of each target lesion for BPA, includ-
ing pouching defects, webs or bands, intimal irregularities, abrupt
vascular narrowing, and complete vascular obstruction (25).
When large amounts of organized thrombi are found in the
proximal portion of the pulmonary artery, BPA is not recom-
mended, as the thrombi cannot be removed using this method and
surgically easily accessible. Moreover, complete obstructions at the
orifices of the segmental arteries that do not show traces of dis-
tal arteries or pouching defects are also unsuitable for BPA, as it is
extremely difficult for the guidewire to pass through these arteries,
although BPA for proximal thrombi has been attempted (26).
Regarding the lesion location, most studies have reported on
the treatment of lesions in the segmental or subsegmental arteries
in peripheral-type CTEPH patients. In PEA, the more distal the
lesion is located, the more difficult the surgery is, and this is why
BPA is mainly performed in the distal pulmonary arteries. How-
ever, when the lesions are located too distally in the subsegmental
pulmonary arteries for the balloon catheter to pass the lesion, BPA
may also be unsuitable.
The success rate for each lesion varies among the lesion types.
In cases of ring-like stenosis and web and abrupt narrowing, a
success rate of almost 100% is achieved, while in cases of the
subtotal obstruction type, the success rate is reported to be approx-
imately 90% (23). Conversely, in pouching defects, the success rate
is <50%.
THE PROCEDURE OF BPA
THE GENERAL PROCEDURE OF BPA
The BPA procedure is approached either through the right internal
jugular vein or the right femoral vein, with the internal jugular vein
route being better for manipulating the guiding catheter into either
the left or right pulmonary artery (12, 14). Using this approach,
two operators are needed: one to manipulate the guiding catheter
and one to manipulate the guidewire. On the other hand, the
femoral vein route has the advantage of one operator being able to
manipulate both the guiding catheter and the guidewire; however,
manipulating the guiding catheter via the right pulmonary arter-
ies is extremely difficult. A 9-French (Fr) sheath is inserted into
the vein, through which a 6-Fr long introducer sheath is advanced
into the pulmonary artery. After the sheaths are inserted, heparin is
administered to reach an activated clotting time of around 200 s,
and an additional 500–1,000 units of heparin are administered
every hour. Subsequently, a 6-Fr guiding catheter (multipurpose
type or the Amplatz type) is advanced into the pulmonary artery
being treated. After performing selective pulmonary angiography,
a 0.014′′ guidewire is used to cross the lesion. When the treatment is
not performed in the upper lobe of the lung, the pulmonary artery
must be stretched as much as possible via deep inhalation from the
patient, as this facilitates the passage of the guidewire. When the
wire has successfully crossed the lesion, a balloon catheter of an
appropriate diameter (1.5–10 mm) is selected to dilate the lesion.
Initially, since it was believed that reperfusion itself was the
cause of BPA-related lung injury, the target area for one treatment
session was limited to two segments on the same side until the
mean PAP fell below 30 mmHg (14). There is also an attempt to
reduce the rate of lung injury by restricting the treatment area (27).
However, the targets and areas for treatment need to be decided
according to the operator’s experience and the patient’s lesion type
and distribution/location. For example, arteries in the middle or
lingular lobes or lesions in the distal to subsegmental arteries are
particularly difficult to treat. Because the effect of treating each
lesion depends on the size of perfusion area of the segmental arter-
ies containing the lesions, there is an expectation that it is more
effective to prioritize treatment of the lesions in the branches of
the inferior lobe. Currently, at our institution, there is no limita-
tion regarding the number of lobes targeted in one session but the
maximum time of radiographic fluoroscopy in a single session is
limited to 60 min. As a consequence, lesions from 4–10 sites are
generally treated in a single session. To enhance the therapeutic
effect of BPA, it is important to make the area of reperfusion large,
which requires repeated treatment with three to four sessions per
patient depending on the treatment goal (14–16).
HOW TO EVALUATE EACH LESION
It is critical to evaluate each lesion type and vessel diameter in
order to determine the appropriate balloon size for performing
angioplasty in BPA. There are several different modalities that have
been recently reported as useful, with some of these modalities
providing us with clearer images of the lesion. However, we need
to consider the feasibility of the modality to be performed in all
patients and during all sessions of BPA, as well as the cost and time
involved in performing each imaging modality.
Pulmonary angiography is considered the conventional and
standard method. To evaluate the lesions in more detail, selec-
tive pulmonary angiography should be performed by injecting
contrast medium from a catheter inserted into the segmental
artery rather than the main pulmonary artery. Intravascular web
and band lesions in subsegmental pulmonary arteries are often
invisible, and subtotal occlusion with a faint trail of contrast
medium in the peripheral arteries can be easily overlooked by ordi-
nary angiography. Accordingly, selective pulmonary angiography
should be routinely performed (Figure 2A).
www.frontiersin.org February 2015 | Volume 2 | Article 4 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ogawa and Matsubara BPA for inoperable CTEPH
Importantly, angiography does not provide information such as
the actual vessel diameter of the lesion or the amount of organized
thrombi occupying the lesion. Therefore, intravascular ultrasound
(IVUS) is used to evaluate the presence of organized thrombi in
the pulmonary arteries and to determine the diameter of the tar-
get; subsequently, the balloon is selected depending on the blood
vessel diameter as measured by the IVUS (14).
There are some experimental methods to evaluate lesions that
are not commonly used. Computed tomography (CT) and/or
contrast-enhanced CT have been reported to detect characteris-
tic lesions in CTEPH (28, 29). In one study, cone beam CT was
compared with contrast-enhanced CT pulmonary angiography
and was found to be useful for the treatment planning of BPA
performed distal to the segmental arteries (30). However, not all
institutions can perform cone beam CT, and its efficacy has not
been compared to that of selective pulmonary angiography. More-
over, the usefulness of optical coherence tomography (OCT) has
been reported. The resolution of OCT is high, and OCT allows
precise determination of the locations of the target lesions of
the pulmonary arteries. It reportedly facilitates the choice of the
appropriate balloon size and length (31). Three-dimensional-OCT
imaging has been reported to be even more useful in evaluating the
lesions (32, 33); however, a downside of this technique is that an
image cannot be obtained without having the blood components
temporarily eliminated by a jet injection of contrast medium. It
sometimes leads to volume overload in severely ill patients with
right heart failure. Further, in cases of highly stenotic lesions, the
OCT catheter wedges at the lesion and cannot obtain information
about lesion beyond the stenosis.
EFFICACY OF BPA
In 2001, Feinstein et al. reported that, with an average of 2.7 BPA
procedures, the mean PAP of their patient group decreased by
9 mmHg (12). Similarly, three studies reported from Japan in 2012
demonstrated the effectiveness of BPA, with a mean PAP reduc-
tion of 14–21 mmHg from baseline (mean PAP, approximately
45 mmHg) with three to four BPA procedures (14–16); refined
BPA demonstrated a larger effect in reducing the mean PAP. We
reported to achieve treatment outcomes equivalent to those for
PEA, observing significant improvements in the WHO functional
class, cardiac index, and pulmonary vascular resistance besides
mean PAP (14).
Two studies based on smaller case series focusing on other
effects of BPA reported on the right ventricular function mea-
sured by echocardiography or cardiovascular magnetic resonance
imaging (34, 35); both reports concluded that the right ventric-
ular volume index was improved after BPA. Further, ventilatory
inefficiency have also been shown to improve after BPA (18, 36).
In our previous report, at the follow-up catheter examina-
tion, significant improvements in the hemodynamics and exercise
capacity were maintained (14). Since there have been no reported
cases of restenosis after BPA to date, its effectiveness seems to
be maintained in the long-term, although only balloon dilatation
without stenting is performed. Larger and longer observations and
analyses are needed. Moreover, currently, there are insufficient data
regarding the long-term survival of patients undergoing BPA. One
report stated that the 2-year survival rate after BPA treatment was
100% (15), and in another report, 85% patients were alive after
51± 30 months of follow-up (18). Considering the high mean
PAP at baseline, these data may offer hope for better survival due
to BPA.
MECHANISM OF IMPROVEMENT OF HEMODYNAMICS BY
BPA
Pulmonary endarterectomy, the gold standard procedure for treat-
ment of CTEPH, involves removal of intraluminal thrombi from
inside the pulmonary arteries; on the other hand, BPA does not
remove thrombi from the pulmonary arteries. Therefore, we ques-
tioned why and how BPA can lead to improving the hemodynamics
without removal of the thrombi. Moreover, we questioned why,
unlike for the coronary arteries, restenosis does not occur despite
the fact that ballooning alone is performed without using any
stents. Previously, we pathologically examined lesions after BPA
and found that the only change in the organized thrombi was
a small incision (37). A subsequent investigation of an autopsy
case revealed that BPA had caused dissection of the tunica media
in the treated sites, and that the organized thrombi had partially
detached from the vascular wall (Figure 3) (38). Thus, this proce-
dure involves the same technique as PEA, only differing in the fact
that the thrombi are not extracted from inside the blood vessel, but
rather forced to one side to make the lumen larger. Following BPA,
parts of the vascular wall exhibited thinning due to dissection;
these thin areas of the vascular wall are then subjected to PAP,
leading to expansion of the lumen diameter over time without
causing restenosis.
COMPLICATIONS OF BPA
COMPLICATION RATE OF BPA
In the first report of BPA, the in-hospital death rate was 5.6%
(12), whereas it was slightly lower, at 0–3.4%, in the following
reports (14–16). Issues associated with BPA include overcoming
lung injury following the procedure. Lung injury was previously
thought to be caused by reperfusion edema (12), which is also
an important postoperative complication of PEA. In severe cases,
mechanical ventilation and percutaneous cardiopulmonary sup-
port are required, and the lung injury may be fatal. Although
BPA could be considered minimally invasive, BPA-related lung
injury reportedly occurs in 9.6–60% of the cases (14, 16, 18). This
frequency is higher than in PEA, suggesting that the mechanism
causing lung injury in BPA may differ from that in PEA. Cytokine
release or a sudden increase in blood flow to the peripheral arter-
ies has been suspected to be the cause of lung injury after PEA
(39), and these mechanisms may also be involved in inducing lung
injury in BPA.
However, in the case of BPA, vascular injury caused by the
guidewire or guiding catheter, or injecting contrast medium with
high pressure may also play a role in inducing lung injury. Indeed,
by reviewing CT images after BPA and pulmonary angiography,
consolidation was observed in the area where BPA was performed
in a previous study, and this could also explain why there may be
a learning curve for reducing BPA-related lung injury (14). The
complication rate for each lesion varies among the lesion types,
similar to the fact that the success rate varies depending on the
lesion types. In cases of ring-like stenosis and web and abrupt
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FIGURE 3 | Histology of a pulmonary artery treated by balloon
pulmonary angioplasty (BPA) [cited from Ref. (38)]. (A) A large lumen was
formed due to dissection in the media of a pulmonary artery by BPA (elastic
tissue stain, low magnification; bar: 1 mm). (B) High magnification of the
dissection site [square in (A); elastic tissue stain]. Dissection occurred in the
middle of the media (arrow). Newly formed intima is observed on the inner
surface (arrowheads). One of the recanalized lumina in the organized thrombi
is also seen on the right.
narrowing, a complication rate is 2%. The complication rate is
approximately 16% in cases of the subtotal obstruction type, and
10% in pouching defects (23).
In addition, after establishing that BPA is actually dissecting
arterial wall (38), some parts of BPA-related lung injury have been
found to occur at the dilation site, resulting in overdilatation or
progression of dissection of the pulmonary arteries. In addition,
even if no signs of complications are observed immediately after
BPA, expansion of the thin vessel walls caused by the detachment
of organized thrombi may progress in cases with extremely high
PAPs, which in turn can lead to oozing ruptures, as observed in aor-
tic dissection or evident pulmonary hemorrhages. There is also a
risk of pulmonary artery perforation or vessel rupture with a guide
wire (14). It may require emergent transcatheter coil embolization
or the use of covered stents (40).
HOW TO REDUCE THE RISK OF LUNG INJURY
Since lung injury was initially thought to be caused by the same
mechanism as that occurring after PEA, we attempted administer-
ing epoprostenol to lower the PAP and using methylprednisolone
and non-invasive positive-pressure ventilation to prevent pul-
monary edema (14). However, our findings suggested that these
measures could not prevent BPA-related lung injury. Later, an
attempt to predict the risk of pulmonary edema resulting from
BPA was made by using pulmonary angiography (27). However,
if one of the major causes for lung injury is catheter-related, as
described above, it might be possible to reduce the risk purely by
refining the technique used. For example, using a guidewire with a
tip load as small as possible, stopping the tip of the guidewire
within the angiographically visible range of the distal vessels,
and injecting the contrast agent gently, may all help reduce the
risk of lung injury. However, these measures alone are likely not
enough, as the complication after BPA has not been eliminated.
Further, when lesions have a large amount of organized thrombi,
balloon dilation itself may cause excessive extension of the pul-
monary vascular wall, likely resulting in vascular injury. Maximum
dilatation is considered to be related to more extensive injuries to
the vascular wall of the lesion. In order to reduce the risk of vascu-
lar wall injuries, the dilatation of the lesion site has to be kept to a
minimum. Feinstein et al. reported that high PAP prior to BPA led
to a high frequency of postoperative lung injury after BPA (12).
Thus, BPA must be performed with particular caution in severe
cases.
When keeping the dilatation of the lesion site small, the effec-
tiveness of BPA decreases. The therapeutic effect of BPA is directly
proportional to the number of vessels treated (14); thus, even
if the dilatation of the lesion sites is kept small, the therapeutic
effect of one session can be maintained by treating several lesions
in one session. However, if the operator has insufficient expe-
rience, treating many lesions at one time leads to an increased
risk of vascular injury at many lesions. Thus, the most realis-
tic countermeasure seems to be increasing the number of BPA
repetitions.
PRESENT LIMITATIONS OF BPA AND FUTURE DIRECTIONS
There is a need for further understanding and information regard-
ing BPA. A novel classification of BPA suitability according to the
lesion type is needed to better select patients who would be most
benefited from BPA. Improved strategies to overcome the com-
plications associated with BPA must be established. BPA-specific
improvements to devices, such as guiding catheters, guidewires,
and balloon catheters, are required. Randomized control trials to
evaluate the superiority of BPA over drug therapy and studies on
the cost-effectiveness of BPA procedures are needed. Furthermore,
long-term data on the risks of restenosis are lacking, as are data
on the need for stenting in these patients. Long-term survival and
efficacy need to be clarified.
There are also demands for BPA performed in adult patients
with isolated peripheral pulmonary artery stenosis (41), and in
such cases, there might be a need for stenting (42). We also do not
know how to treat very distal arteries with a diameter <100µm,
which can currently not be treated either by PEA or BPA (37).
www.frontiersin.org February 2015 | Volume 2 | Article 4 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ogawa and Matsubara BPA for inoperable CTEPH
CONCLUSION
Balloon pulmonary angioplasty is a novel treatment that can
potentially provide marked improvements in subjective symptoms
and hemodynamics in CTEPH patients ineligible for PEA. How-
ever, further refinements of the strategy to reduce complications,
improvements in the simplicity of the treatment, and evaluation
of the long-term follow-up results are needed before BPA can be
recommended as an established treatment for CTEPH.
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